Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have earned an average rating of “Hold” from the thirty ratings firms that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $469.27.
A number of analysts have commented on REGN shares. JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, October 31st. Evercore ISI reduced their target price on Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating for the company in a report on Thursday, November 16th. Barclays lowered Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and cut their price objective for the stock from $450.00 to $395.00 in a report on Friday, October 20th. Guggenheim reaffirmed a “buy” rating and issued a $540.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, October 23rd. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $490.00 price objective (up previously from $450.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded up $0.25 during trading on Friday, hitting $371.53. The company’s stock had a trading volume of 662,124 shares, compared to its average volume of 660,649. The company has a market cap of $39,920.00, a price-to-earnings ratio of 33.74, a price-to-earnings-growth ratio of 1.44 and a beta of 1.52. Regeneron Pharmaceuticals has a twelve month low of $340.09 and a twelve month high of $543.55. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in REGN. Harding Loevner LP lifted its position in Regeneron Pharmaceuticals by 589.2% during the third quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock valued at $286,619,000 after purchasing an additional 3,131,966 shares in the last quarter. Janus Henderson Group PLC lifted its position in Regeneron Pharmaceuticals by 15,495.4% during the second quarter. Janus Henderson Group PLC now owns 1,562,970 shares of the biopharmaceutical company’s stock valued at $767,637,000 after purchasing an additional 1,552,948 shares in the last quarter. FMR LLC lifted its position in Regeneron Pharmaceuticals by 6.3% during the second quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock valued at $3,457,569,000 after purchasing an additional 416,192 shares in the last quarter. Old Mutual Global Investors UK Ltd. lifted its position in Regeneron Pharmaceuticals by 500,446.2% during the third quarter. Old Mutual Global Investors UK Ltd. now owns 325,355 shares of the biopharmaceutical company’s stock valued at $145,472,000 after purchasing an additional 325,290 shares in the last quarter. Finally, PointState Capital LP purchased a new position in Regeneron Pharmaceuticals during the second quarter valued at $78,199,000. Institutional investors own 66.63% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.